Anthera Pharmaceuticals Reports 2011 Second Quarter Financial Results and Operatio... ( HAYWARD Calif. July 29 2011 /- Anther...)

Anthera Pharmaceuticals Reports 2011 Second Quarter Financial Results and Operational Update

Date:7/29/2011

HAYWARD, Calif., July 29, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), today announced financial results and business highlights for the quarter ended June 30, 2011.

Financial Results:

Total operating expenses for the second quarter ended June 30, 2011 were $22.7 million, as compared to $7.9 million for the same period in 2010. For the six months ended June 30, 2011, total operating expenses were $41.3 million, as compared to $14.4 million for the same period in 2010. Increased operating expenses in the second quarter of 2011 can be attributed to accelerating enrollment of our Phase 3 VISTA-16 cardiovascular study (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) following the recent completion of the interim biomarker analysis. VISTA-16 is an event driven study in Acute Coronary Syndrome (ACS) patients studying the benefit of varespladib anti-inflammatory treatment in high risk patients. Additionally, enrollment of Anthera's Phase 2b Lupus study, PEARL-SC (A Randomized, Double-Blind Phase 2b Study to Evaluate the Efficacy, Safety, and Tolerability of A623 AdministRation in Subjects with Systemic Lupus Erythematosus) has exceeded expectations. During the second quarter we accelerated manufacturing activity related to the development of blisibimod (A-623), our large molecule inhibitor of BAFF being dosed in the PEARL-SC clinical study, which also contributed to incremental expenses.

Anthera ended the second quarter of 2011 with approximately $112.1 million in cash and cash equivalents and short-term investments, which includes approximately $54.0 million of net proceeds received from a public offering, which closed on June 8, 2011. This is compared to $78.5 million in cash and cash equivalents and short-term investments for the first quarter
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
5. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
6. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
9. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
10. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
11. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors

Post Your Comments:

(Date:5/23/2013)... , May 23, 2013 Israel Brain ... 2013 , Israel,s 1 st ... 14 th -15 th in Tel Aviv ... innovative city in the world by the Wall Street ... BrainTech Israel 2013 will showcase the latest breakthroughs in ...

(Date:5/23/2013)... , May 23, 2013 EarlySense, ... today that the prize for ,Best Novel Idea, at ... Medical Emergency Teams International Conference, hosted this year in ... awarded to a clinical research team studying the impact ... Hospital in Los Angeles . The ...

(Date:5/23/2013)... May 23, 2013 SynCardia Systems, Inc. ( ... FDA, Health Canada and CE ( Europe ... Glasgow Science Centre in Scotland , ... the SynCardia temporary Total Artificial Heart powered ... $3 million Bodyworks Exhibition, one of the most advanced ...

Breaking Medicine Technology:Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 2 Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 3 Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference 2 Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference 3 Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference 4 Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 2 Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 3

[0] Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference [0] Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference [0] Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition

... -- , - Cipralex Better Tolerated and at ... A/S announces new study data published today in ... (escitalopram) was superior to duloxetine in the acute,treatment ... was,at least as efficacious in long-term treatment(1). The ...

... for CPX-1 presented at ASCO confirm safety findings,and ... patients with,colorectal and other types of cancer., PRINCETON, ... positive safety and efficacy results from,its Phase I ... with heavily pre-treated, advanced solid,tumors. Results were presented ...

Cached Medicine Technology:Newly Published Data Demonstrates Superiority of Cipralex Over,Duloxetine for Acute Treatment of Depression 2 Newly Published Data Demonstrates Superiority of Cipralex Over,Duloxetine for Acute Treatment of Depression 3 Newly Published Data Demonstrates Superiority of Cipralex Over,Duloxetine for Acute Treatment of Depression 4 Newly Published Data Demonstrates Superiority of Cipralex Over,Duloxetine for Acute Treatment of Depression 5 Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer,Patients Treated with Therapy Based on Ratiometric Dosing 2 Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer,Patients Treated with Therapy Based on Ratiometric Dosing 3

Newly Published Data Demonstrates Superiority of Cipralex Over,Duloxetine for Acute Treatment of Depression Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer,Patients Treated with Therapy Based on Ratiometric Dosing

(Date:5/23/2013)... News) -- A modified version of the polio ... preliminary research suggests. Scientists at Duke Cancer ... PVSRIPO, uses an engineered form of the virus ... cancer cells. The therapy shows promise in the ... brain tumor, they said. "These early results ...

(Date:5/23/2013)... (May 23, 2013)Don,t doubt it when a woman harried ... remembering things. A new study published online in ... Society (NAMS), helps confirm with objective tests that what ... In the past, some studies showed that hot flashes ... studies showed that, even though there was a relationship ...

(Date:5/23/2013)... PA (PRWEB) May 23, 2013 ... Teaching Site, offering a comprehensive babysitting training course for ... program was developed by Indianapolis pediatrician Dr. Patricia Keener ... the care of an adult sitter who didn’t know ... well-rounded youth development program with a medical basis that ...

(Date:5/23/2013)... anti-cancer drug about to be tested in a clinical ... possible treatment for Alzheimer,s disease has failed to work ... Alzheimer,s patients, according to results of a study by ... professor of neuroscience affiliated with the Evelyn F. and ... Florida, emphasized the importance of verifying promising research results ...

(Date:5/23/2013)... The Rottenstein Law Group LLP, a New York-based nationwide ... Information Center at http://www.rotlaw.com/tylenol , dedicated to issues ... considering filing lawsuits. , The painkiller Tylenol (acetaminophen) ... according to a 2009 report from the U.S. Food ... FDA warned consumers against using more than the recommended ...

Breaking Medicine News(10 mins):Health News:Modified Polio Virus May Help Fight Brain Tumors, Study Suggests 2 Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 2 Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 3 Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 2 Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 3 Health News:Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center 2

[0] Modified Polio Virus May Help Fight Brain Tumors, Study Suggests [0] It's not your imagination: Memory gets muddled at menopause [0] Susquehanna Health Offers Safe Sitter Course for Tweens and Teens [0] Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study [0] Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center

... , ... new market research report is available in its catalogue: ... , http://www.reportlinker.com/p0166825/Antibiotic-Resistance-and-Antibiotic-Technologies-Global-Markets.html , Provide an in-depth ... antibiotics technologies , Offer an analysis of antibiotics resistance ...

... , WEDNESDAY, Dec. 2 (HealthDay News) -- In the ... patients in the United States have improved modestly, a ... more than 100,000 patients diagnosed with stage 4 non-small ... patient information was in the U.S. National Cancer Institute,s ...

... have metabolic syndrome, study finds , WEDNESDAY, Dec. 2 ... overweight college football players from being at higher risk ... disease, a new study suggests. , Researchers studied linemen ... obese. Of those, 42 percent had metabolic syndrome, a ...

... Va., Dec. 2 By now, most people have heard of ... the latest product on the market is now available at the ... at the amazingly low price of $14.99. , "This new product ... very low price, before making a bigger investment in a smokeless ...

... MONTREAL, Dec. 2 /PRNewswire/ - As part of its continued ... part of Pfizer, has pledged more than 40 million international ... Hemophilia (WFH). This is the largest donation ever made to ... impact to advance the WFH,s goals. , "This donation will ...

... , KNOXVILLE, Tenn., Dec. 2 TeamHealth ( www.teamhealth.com ... of Naples-based Emergency Physicians of Naples, LLC (EPN). Since ... Healthcare System to staff the emergency facilities at the Downtown ... EPN also provides the staffing for two stand-alone urgent care ...

Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets Gains Made in Lung Cancer Survival Oversized College Football Players May Face Heart Risks A Smokeless Holiday Season? Premium Electronic Cigarette Announces New Disposable Smokeless Cigarette Product The WFH receives the largest humanitarian aid donation in its history - Donation represents more than 40 million international units to the WFH TeamHealth Acquires Emergency Physicians of Naples, LLC

... Ultra Strep A Test is a color ... DLT uses antibody labeled color particles coated ... device. DLT allows greater sensitivity than the ... In the test procedure, a throat swab ...

... Fertell test is an easy to use, one ... reserve by means of determining the amount of ... sample. The test is performed two days after ... menstrual cycle) and is similar in design and ...

... The Cholestech GDX System delivers an unmatched combination ... ideal solution for assessing and monitoring a patient's ... demo, click here ., ,The CLIA-waived Cholestech ... A1C results in less than 5 minutes. The ...

... The Cholestech LDX System, using patented, ... plus glucose and ALT in only 5 ... new ALT test, you can get immediate ... measurement capabilities is not the only advantage ...

Medicine Products:

OSOM Ultra 25 Strep A Fertell Female Fertility Test Cholestech GDX System LDX Analyzer